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Abstract
This study examined whether longitudinal adherence profiles mediated the relationship between a brief
adherence intervention and glycemic control among patients with type 2 diabetes. Adherence was assessed
using the Medication Event Monitoring System. Longitudinal analysis via growth curve mixture modeling was
carried out to classify patients according to patterns of adherence to oral hypoglycemic agents. Hemoglobin
A1c assays were used to measure glycemic control as the clinical outcome. Across the whole sample,
longitudinal adherence profiles mediated 35.2% (13.2, 81.0%) of the effect of a brief adherence intervention
on glycemic control [from odds ratio (OR) = 8.48, 95% confidence interval (CI) (3.24, 22.2) to 4.00, 95% CI
(1.34, 11.93)]. Our results suggest that patients in the intervention had better glycemic control largely due to
their greater likelihood of adherence to oral hypoglycemic agents.
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Abstract
This study examined whether longitudinal adherence profiles mediated the relationship between a 
brief adherence intervention and glycemic control among patients with Type 2 diabetes. 
Adherence was assessed using the Medication Event Monitoring System (MEMS). Longitudinal 
analysis via growth curve mixture modeling was carried out to classify patients according to 
patterns of adherence to oral hypoglycemic agents. Hemoglobin A1c (HbA1c) assays were used to 
measure glycemic control as the clinical outcome. Across the whole sample, longitudinal 
adherence profiles mediated 35.2% (13.2%, 81.0%) of the effect of a brief adherence intervention 
on glycemic control (from odds ratio (OR) = 8.48, 95% CI (3.24, 22.2) to 4.00, 95% CI (1.34, 
11.93)). Our results suggest that patients in the intervention had better glycemic control largely 
due to their greater likelihood of adherence to oral hypoglycemic agents.
Keywords
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INTRODUCTION
Interventions targeting adherence to medications for diabetes have been successful in 
improving clinical outcomes (Vermeire et al., 2005). However, the factors comprising an 
effective adherence intervention have yet to be fully elucidated. Evidence suggests that 
interventions tailored specifically to the individual which address a wider range of barriers 
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may be the most effective in producing clinically meaningful results (e.g. (Haynes et al., 
2008)). Education alone has not been found to be sufficient for producing significant 
behavior change (Mundt et al., 2001). While many adherence enhancing interventions have 
succeeded in improving glycemic control, it remains unclear whether improved glycemic 
control results from improved patient adherence.
The focus of intervention research on “do they work?” not “why do they work?” leaves a 
substantial gap in understanding what comprises a successful adherence intervention. 
Mediation analysis is an important method for examining the mechanism of intervention 
trials. A mediator accounts for the variation between a predictor and an outcome, while 
moderators indicate when effects might be seen, mediators specify how or why an effect 
occurred (Baron & Kenny, 1986). Given findings that interventions improve adherence, and 
interventions improve clinical outcomes, the investigation of whether improvements in a 
clinical outcome are due to improvements in adherence occasioned by the intervention is an 
important next step in scientific inquiry (Stratton et al., 2000; Turner et al., 1999). Prior 
work has found that diabetes adherence interventions improve adherence and glycemic 
control but these studies have not examined mediation by medication adherence (e.g. (Aliha 
et al., 2013; J. D. Piette et al., 2000)). Determinants of behavior change (e.g. socio-
ecological resources and self-efficacy) have been examined in relation to diabetes 
intervention effects on behaviors and clinical outcomes (Barrera et al., 2008; Sweet et al., 
2009; Trief et al., 2009). Mediation of diabetes intervention effects on clinical outcomes by 
behavior (e.g. insulin use and self-monitoring practices) has also been investigated (Brega et 
al., 2012; J. Piette et al., 2013). Only one identified study examined the influence of 
adherence behavior to diabetes self-care as a mediator of an intervention’s effect on glucose 
control (Trief et al., 2013). To our knowledge, no known studies have examined mediation 
of a diabetes intervention effect by longitudinal profiles of oral hypoglycemic agent 
adherence.
Our goal was to examine longitudinal profiles of oral hypoglycemic adherence as a mediator 
of a brief adherence intervention on glycemic control. The model in Figure 1 represents a set 
of testable hypotheses about how the intervention and improved glucose control may be 
related to one another through their association with oral hypoglycemic agent adherence 
profile type. Our model was tested in four stages: 1) the association of intervention 
assignment and glucose control; 2) the association of intervention assignment with oral 
hypoglycemic agent adherence profile type; 3) the association of adherence profile type and 
glucose control; and 4) the association of intervention and improved glucose control with 
terms representing oral hypoglycemic agent adherence profile type in the model to test for 
mediation.
METHODS
Study Sample
A Brief Intervention to Improve Adherence through Integrated Management of type 2 
Diabetes Mellitus and Depression Treatment was a randomized controlled trial designed to 
examine whether an integrated care intervention (IC intervention) improved adherence to 
oral hypoglycemic agents, glycemic control, and depression among primary care patients 
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with type 2 diabetes mellitus (type 2 DM). The study protocol was approved by the 
University of Pennsylvania Institutional Review Board. The intervention is described in 
detail elsewhere (Bogner et al., 2012).
Recruitment
Patients were recruited from three primary care practices in Philadelphia, Pennsylvania. 
From April 2010 to April 2011, patients with a diagnosis of type 2 DM and a prescription 
for an oral hypoglycemic agent within the past year were identified through electronic 
medical records. Patients with an upcoming appointment who met initial criteria were 
approached for further screening. Eligibility criteria included: 1) aged 30 years and older; 2) 
a diagnosis of type 2 DM; 3) a current prescription for an oral hypoglycemic agent; and 4) a 
current prescription for an antidepressant. The age cut-off of 30 years and older was chosen 
because of its significance for the detection, screening, and intervention for diabetic patients 
(Kahn et al., 2010). Patients with a current prescription for an antidepressant were included 
because diabetes and depression are two of the most common co-morbid problems seen in 
primary care settings (Eaton, 2002). Exclusion criteria included: 1) inability to give 
informed consent; 2) significant cognitive impairment at baseline (Mini-Mental State 
Examination (MMSE) <21) (Crum et al., 1993); 3) residence in a care facility that provides 
medications on schedule; and 4) unwillingness or inability to use the Medication Event 
Monitoring System (MEMS). The intervention aimed to address adherence to patients’ 
entire medication treatment regimen including insulin use, and thus insulin users were not 
excluded from participation. Patients whose caregivers assisted with their medications were 
not excluded from participation. MEMS caps on pill bottles record the exact data and time 
of medication container opening. Patients were randomly assigned to the IC intervention or 
usual care.
Study Design
This trial consisted of two phases: the run-in phase and the randomized controlled trial 
phase. The purpose of the 2-week run-in phase was to collect pre-intervention adherence 
rates for all patients. During this phase data were also collected on demographics, depressive 
symptoms, and glycosylated hemoglobin. No intervention was performed during this phase. 
Following completion of the 2-week run-in phase, patients entered phase 2 of the study in 
which they were randomized within each practice by flip of a coin to either the IC 
intervention or usual care. Physicians were told which patients were enrolled in the IC 
intervention to allow for collaboration with the IC manager, but were blinded to enrollment 
in the usual care group.
Integrated Care Intervention (IC Intervention)
For patients assigned to the intervention, integrated care managers offered education, 
guideline-based treatment recommendations, and monitored adherence and clinical status in 
collaboration with physicians. The integrated care manager worked with patients 
individually to address patient-level factors involved in adherence to oral hypoglycemic 
agents including depression, chronic medical conditions, function, cognition, lack of social 
support, cost of medications, experiencing side effects, and past experiences with 
medications. Patient-level factors were addressed through a variety of activities including in 
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person sessions, telephone contacts, and collaborating with the physician. Through in person 
sessions and telephone conversations the IC manager provided education about type 2 DM; 
helped patients identify target symptoms; provided a rationale for the rationale for use of 
oral hypoglycemic agents; assessed for side-effects and needed assistance with self-
management; assessed for progress (e.g. improvement in finger stick results); assisted with 
referrals; and monitored and responded to life-threatening symptoms (e.g. chest pain). The 
intervention was presented to patients as a supplement to, rather than a replacement for, 
existing primary care treatment.
Over a three-month period patients had three 30-minute in person sessions (baseline, 6 
weeks and 12 weeks) and two 15-minute telephone monitoring contacts. Integrated care 
managers were two research coordinators (one Master’s level and one bachelor’s level) who 
administered all intervention activities. Prior to trial initiation, the integrated care managers 
received training on pharmacotherapy for type 2 DM management during weekly clinical 
sessions with the principal investigator.
Usual Care
Patients in the usual care group underwent the same assessments at the same time points 
(baseline, 6, and 12 weeks) as the patients in the IC intervention. As in the intervention 
group, assessments were conducted in person. Research assistants conducted all assessments 
and were blinded to patients’ randomization status.
Measurement Strategy
Potential study patients were screened for cognitive impairment using the MMSE, a short 
standardized mental status examination widely employed for clinical and research purposes 
(Folstein et al., 1975). Patients were asked whether they resided in a care facility that 
provided medications on schedule and whether they were unwilling or unable to use MEMS. 
At baseline sociodemographic characteristics were assessed using standard questions. 
Functional status was measured using the Medical Outcomes Study Short Form (SF-36) 
(Stewart et al., 1988). Adherence to oral hypoglycemic agents was measured during the 2-
week run-in phase, and at 6 and 12 weeks, using electronic monitoring data obtained from 
MEMS Caps.
At baseline and 12 weeks blood glycemic control was assessed in accordance with American 
Diabetes Association Guidelines (American Diabetes Association, 2014). Hemoglobin A1c 
(HbA1c) assays were performed with the in2it A1C Analyzer. Point of care testing using this 
device has acceptable precision and agreement in comparison with laboratory services 
(Moridani et al., 2003).
Analytic strategy
We calculated descriptive statistics to compare baseline patient characteristics in the 
intervention group to usual care using the Fishers’ exact test and Wilcoxon rank sum test 
(for categorical and continuous variables respectively). For the analysis of mediation, we 
used our prior classifications of patients into latent longitudinal adherence profile (de Vries 
McClintock et al., in press). To obtain these profiles, we employed recent developments in 
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statistical assessment of treatment effects or of course of depression in primary care, 
especially the general growth curve mixture model (GGCMM) (Jo & Muthen, 2001; B. 
Muthen et al., 2002; B. O. Muthen, 2001; B. O. Muthen & Shedden, 1999) as in prior work 
(e.g. (Elliott et al., 2005; Lin et al., 2007)). Binary indicators of adherence measurements 
were assessed by MEMS caps at weekly intervals over a 12-week period. Patients were 
categorized as adherent if they took at least 80% of their pills in the interval (George et al., 
2000). Otherwise, patients were considered to be nonadherent. The GGCMM analyses 
produced parameters that describe the adherence profiles of each class as well as estimated 
posterior probabilities of unobserved class membership for each patient. Patients were 
classified into categories of longitudinal adherence profile types based on the largest 
posterior probability of membership across the classes. Longitudinal adherence profile types 
identified were: adherent, increasing adherence, and nonadherent. We analyzed the resulting 
categorical variable for longitudinal oral hypoglycemic agent adherence profile types as a 
mediator.
The 4-step approach of Baron and Kenny provides a theoretical and practical foundation for 
the assessment of mediation (Baron & Kenny, 1986). The definition of mediation is met if 
the following conditions hold: 1) the IC intervention improves the clinical outcome (blood 
glucose control); 2) the IC intervention improves the potential mediator (longitudinal oral 
hypoglycemic agent adherence profile type); 3) improvements in the mediator are associated 
with improvements in the clinical outcome, controlling for the intervention's effect on the 
outcome; and 4) adjusting for the mediator, the clinical outcome is attenuated and no longer 
significant. Partial mediation is present if the intervention coefficient is attenuated but there 
is still a significant effect of the intervention on glucose control. An additional requirement 
of causal mediation is that changes in the mediators occur in time before changes in the 
outcome. Adherence is measured over time before the outcome of interest, blood glucose 
control. Following MacKinnon et al., we used a threshold of 15% for sufficient change in 
the coefficients of intervention as assessment of attenuation for mediation (D. P. MacKinnon 
et al., 2000; D. P. MacKinnon et al., 2002). The first three conditions have been examined in 
prior work, and meet sufficient criteria for mediation (Bogner et al., 2012; de Vries 
McClintock et al., in press). For condition 2, patients in the intervention condition were 
more likely to have an adherent pattern compared to a nonadherent pattern (OR = 11.6, 95% 
CI [4.08, 32.9]). Patients in the intervention condition were more likely to have an 
increasing adherence pattern compared to a nonadherent pattern (OR= 41.31, 95% CI 
[13.87, 123.03]) (de Vries McClintock et al., in press). For this analysis we are examining 
whether criteria for condition number 4 is met.
Based on our prior work examining the relationship between intervention condition and 
glucose control, patients were analyzed according to the treatment to which they were 
randomized (intent-to-treat). Practice site was included in the model to account for 
unmeasured factors related to clustering by practice. The model adjusted for baseline HbA1c. 
Logistic regression related latent class variables to the clinical outcome of glucose control at 
12 weeks for the entire sample. To assess whether stratified analysis was warranted we 
examined baseline interactions (Baron & Kenny, 1986). Based on the presence of a 
significant interaction (p<.001), we then conducted stratified analysis of patients with and 
without HbA1c ≥8% at baseline. As recommended by clinical guidelines, our outcome of 
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glucose control was assessed using a cutoff of HbA1c < 7% at 12 weeks (American Diabetes 
Association, 2014). The results are presented in the form of odds ratios and 95% confidence 
intervals. As recommended by Hayes (Hayes, 2009), we have modernized the application of 
Baron and Kenny by applying the bootstrapping technique, one of the more valid and 
powerful methods for testing intervening variable effects and generating bias-corrected 
confidence intervals for indirect effects. The size of the indirect effect and bias-corrected 
95% CI was obtained through the bootstrap techniques with 5000 replications (Preacher & 
Hayes, 2008; Vanderweele & Vansteelandt, 2010). We set α at 0.05, recognizing that tests 
of statistical significance are approximations that serve as aids to inference. The GGCMM 
was fitted using Mplus version 7 (Muthén & Muthén, 1998) and other analyses were 
conducted in STATA version 12 for Windows (STATA Corporation, College Station, TX).
RESULTS
Study sample
The CONSORT flow diagram for this trial has been published elsewhere (Bogner et al., 
2012). In brief, of 715 patients with type 2 DM were identified by electronic medical 
records. In all, 265 were eligible based on initial inclusion criteria and approached, and 190 
were enrolled based on additional inclusion criteria (71.7% participation rate). After a 2-
week run-in phase in which adherence to medications was assessed, consent was obtained. 
At the 2-week visit, 8 patients were no longer eligible for participation (5 physicians had 
discontinued antidepressants, 1 physician had discontinued an oral hypoglycemic agent, and 
2 patients were lost to follow-up). The remaining 182 patients were randomized to the IC 
intervention or usual care. Subsequently, 2 patients in the IC intervention were lost to 
follow-up leaving 180 patients who completed all study visits. For these 180 patients 
complete information on baseline covariates and on the clinical outcome of glucose control 
at 12 weeks was obtained. The mean age of our sample was 57.4 years (standard deviation 
(s.d.) 9.5 years, range 32 to 84 years). One hundred and twenty-two (67.8%) of the patients 
were women. The self-identified race of patients was 65 white (36.1%), 102 African-
American (56.7%), 7 Hispanic (3.9%), and 6 (3.3%) who self-identified as ‘other.’ In all, 69 
persons (38.33%) were married and 29 persons (16.1%) had less than a high school 
education. The mean number of medical conditions was 7.3 (s.d. 3.2) and the mean MMSE 
score was 28.2 (s.d. 2.3). The baseline patient characteristics of the study sample are shown 
in Table 1.
Mediation of intervention group effect on glycemic control by adherence profile type
In our prior work, a series of general growth curve mixture models (GGCMM) were fitted to 
the MEMS data. The three-pattern model presented in Figure 2 improved the model fit over 
the two- and four-pattern models yielding three adherence profile types. The three adherence 
profile types identified and employed for this analysis were: adherent (n=67), increasing 
adherence (n=52), and nonadherent (n=61) (de Vries McClintock et al., in press). Table 2 
shows the effect of the intervention on glycemic control in models with and without 
mediation by adherence profile types. Patients randomized to the IC intervention were more 
likely to achieve a HbA1c <7% in comparison with patients in the usual care group at 12 
weeks (p<0.001). When including the mediator (adherence profile type) in the model 
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evaluating achievement of HbA1c <7% at 12 weeks, 35.2%, (95% confidence interval (CI) 
(13.2%, 81.0%)) of the effect was mediated by adherence profile type (from odds ratio (OR) 
= 8.48, 95% CI (3.24, 22.2) to 4.00, 95% CI (1.34, 11.93)) (Table 2).
Mediation of intervention group effect on glycemic control by adherence profile type 
stratified by HbA1c ≥ 8%
Additional multivariate analyses were performed to examine mediation by patients with and 
without HbA1c ≥8%. Among patients with HbA1c ≥8%, patients randomized to the IC 
intervention were more likely to achieve an HbA1c <7% in comparison with patients in the 
usual care group at 12 weeks (intervention 25.0% vs. usual care 4.8%; p<0.05). When 
including the mediator (adherence profile type) in the model evaluating achievement of 
HbA1c <7% at 12 weeks, 63.5% of the effect was mediated by adherence profile type and 
the relationship between the intervention and glucose control was no longer significant 
(from OR=12.41, 95% CI (1.21, 654.35) to 2.51, 95% CI (0.12, 159.82)).
Among patients with an HbA1c <8%, patients randomized to the IC intervention were more 
likely to achieve HbA1c <7% in comparison with patients in the usual care group at 12 
weeks (intervention 89.7% vs. usual care 62.7%; p<0.01). When including the mediator 
(adherence profile type) in the model evaluating achievement of HbA1c <7% at 12 weeks, 
only 26.4% of the effect was mediated by adherence profile type (from OR= 4.77, 95% CI 
(1.87, 12.17) to 3.16, 95% CI (1.05, 9.49)).
DISCUSSION
The principal finding of this study is that the relationship between a brief adherence 
intervention and glycemic control was partially mediated by oral hypoglycemic agent 
adherence profile type over 12 weeks across the entire sample. Among patients with a 
HbA1c ≥8% at baseline, the relationship between the brief adherence intervention and 
glycemic control was fully mediated by oral hypoglycemic agent adherence profile type 
over 12 weeks. A brief intervention’s effect on improved glycemic control among patients 
with a HbA1c ≥8% was due to their greater likelihood of adherence to oral hypoglycemic 
agents. To our knowledge, this is the first report of mediation by adherence of an association 
between a diabetes adherence intervention and glycemic control.
Before discussing the implications of our findings, the limitations of our study must be 
considered. First, our results were obtained from patients who received care at three primary 
care sites that might not be representative of most primary care practices. However, the three 
practices were diverse and varied in size and were probably similar to other primary care 
practices in the region. Second, all methods for assessing adherence have limitations. We 
chose to use microelectronic monitors on pill bottles as our primary measure of adherence 
because microelectronic monitors have a low failure rate (George et al., 2000) and may be 
more sensitive than other adherence measures (Farmer, 1999). The validity and reliability of 
electronic monitoring of adherence provides a reference standard by which other adherence 
assessment methods can be examined (Nakonezny et al., 2008; Osterberg & Blaschke, 
2005). Third, while the 80% threshold for adherence has been assessed in some clinical 
research (e.g.(George et al., 2000)), the clinical relevance of this threshold has not been 
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tested for many medications. Fourth, we utilized only one method of mediation analysis. 
Other approaches to mediation analysis (Hayes, 2009) with different assumptions may yield 
different results (D. Mackinnon, 2008). Fifth, a current prescription for an antidepressant 
was part of our inclusion criteria. Therefore, our findings may be most relevant to patients 
with diabetes as well as depression. Finally, point-of-care testing for HbA1c, is imperfect in 
its assessment (Lenters-Westra & Slingerland, 2010). However, misclassification would 
likely be nondifferential thus biasing estimates toward the null. Drawbacks of point of care 
testing for HbA1c must be weighed in relation to other factors such as cost-effectiveness and 
practicality of use in the clinical setting.
Despite limitations, our results deserve attention because we attempted to characterize the 
relationship between a brief adherence intervention, oral hypoglycemic agent adherence 
profile type and glycemic control. Our work is consistent with Trief et al. who found that a 
telemedicine case management intervention among patients with type 2 DM was mediated 
by self-reported adherence to diabetes self-care. Trief and colleagues examined mediation 
by self-reported adherence to recommended blood glucose testing, dietary control, exercise, 
and foot care. In contrast, the focus in our study was on adherence to medications for 
diabetes because of the clinical significance of diabetes medication taking in clinical 
prognosis (Rasmussen et al., 2007). Our use of general growth curve mixture models 
allowed us to distinguish distinct patterns of adherence over time instead of assessing 
adherence through proportions at singular point(s) in time with no assessment of variation 
over time and group classification. Furthermore, this approach utilizes all adherence data 
producing estimated posterior probabilities of unobserved class membership for each 
patient, thus improving precision by accounting for effects of the intervention and baseline 
covariates on adherence. In summary, our findings build and expand on prior work by 
demonstrating that longitudinal adherence profiles assessed by an objective measure of 
medication adherence mediate the relationship between a brief adherence intervention and 
glycemic control for patients with HbA1c ≥8% at baseline.
Specifically, in our examination across the full sample, our results demonstrate partial 
mediation. While the intervention coefficient is attenuated, there is still a significant 
relationship between the intervention and glucose control. Partial mediation may be due to 
the comprehensive nature of the adherence intervention in which adherence barriers were 
targeted using a multi-faceted approach. Improved glycemic control may have occurred 
through mechanisms other than improved adherence (e.g. diet and exercise) as the 
interventionist aimed to improve through an array of avenues including social support and 
the development of problem solving skills. In addition, the therapeutic alliance, defined 
broadly as the collaborative bond between patient and provider, has been identified as a key 
element of patient-provider relationship not only for psychotherapy, but also for 
pharmacotherapy. Better therapeutic alliance is associated with better adherence to 
medications as well as treatment outcomes (Krupnick et al., 1996; McCabe et al., 2012). The 
therapeutic alliance may be tapping into patient’s subjective assessment of the social and 
personal experiences with their provider or in this case the interventionist. If patients had a 
stronger bond with an interventionist, they may be more willing to follow the 
interventionist’s advice on treatment adherence and, in turn, may have been more adherent 
leading to better clinical outcomes.
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Our finding that mediation was present to a greater extent for patients with a HbA1c ≥8% 
compared to patients with a HbA1c <8% at baseline supports a more complex 
conceptualization of mediation effects in which mediators may differ by baseline 
characteristics of the patient. It may be necessary to develop interventions that incorporate 
mediators based on individual patients. In other words, some mediators may work for some 
patients but not for others, and intervention development may need to be customized 
accordingly. Mediators of intervention effect have been identified as factors that may be 
critical for tailoring (Small et al., 2012). Methodological developments allow for tailoring 
over time throughout the interval of intervention deployment, even for covariates that occur 
post-randomization (Almirall et al., 2012). Further research with such designs (e.g. adaptive 
trials) may have both important methodological and clinical implications.
Building on prior evidence indicating that interventions targeting adherence improve clinical 
outcomes (e.g. (Vermeire et al., 2005)), we have sought to help elucidate the mechanism by 
which interventions may influence outcomes. Our results indicate that patterns of adherence 
over time are critical in explaining diabetes intervention effects on glycemic control. The 
prospective design of the study lends strength to the idea that patterns of adherence over 
time can signal how effective an intervention may be in improving outcomes. Patterns of 
adherence over time may be an important marker for subsequent clinical outcomes and 
therefore are an important target for intervention and follow-up.
The National Institutes of Health (NIH) Adherence Research Network has identified 
improving adherence as a top priority. This inter-disciplinary initiative notes that increased 
adherence to medication regimens promises substantial improvements in public health as 
well as savings in healthcare costs. A lack of compliance with recommended treatment 
regimens has been identified as a causal factor in preventable morbidity and mortality in 
numerous studies and across many illnesses (Osterberg & Blaschke, 2005). Thus, efforts to 
improve treatment adherence has been labeled the "next frontier in (healthcare) quality 
improvement"(Heidenreich, 2004). Our study provides additional evidence of the public 
health importance of addressing adherence. The effectiveness of diabetes interventions in 
improving clinical outcomes may be substantially mediated by patterns of adherence over 
time. Collaborative networks between policy initiatives, healthcare networks and medical 
settings are needed to develop sustainable adherence programs.
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Figure 1. 
Model of the potential relationship of the intervention, oral hypoglycemic agent adherence 
profile type, and glycemic control.
Note: Oral hypoglycemic agent adherence profile types were obtained from general growth 
curve mixture models in which patients were classified into categories of longitudinal 
adherence profile types based on the largest posterior probability of membership across the 
classes. Three longitudinal adherence profile types were: adherent, increasing adherence, 
and nonadherent.
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Figure 2. 
General growth curve mixture model analysis of adherence to oral hypoglycemic agents 
(number of patients in each class with plotted conditional probabilities) (n=180).
Note: Data gathered from 2010–2011.
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Table 1
Baseline characteristics. P-values represent comparisons according to Fisher’s Exact test and the Wilcoxon 
rank sum test for categorical or continuous data, respectively.
Usual Care
(n=88)
Intervention
(n=92)
P
value
Sociodemographic characteristics
Age, mean in years (s.d.) 57.1 (9.6) 57.8 (9.4) .75
African American, n (%) 48 (54.5%) 54 (58.7%)
White, n (%) 36 (40.9%) 29 (31.5%) .28
Hispanic, n (%) 3 (3.4%) 4 (4.3%)
Other, n (%) 1 (1.1%) 5 (5.4%)
Gender, women n (%) 58 (65.9%) 64 (69.6%) .64
Less than HS education, n (%) 15 (17.0%) 14 (15.2%) .84
Type 2 diabetes mellitus
Years of diabetes, mean (s.d.) 12.0 (11.8) 10.5 (10.2) .37
HbA1c, mean (s.d.) 7.0 (1.9) 7.2 (1.8) .22
Depression
PHQ-9, mean (s.d.) 9.9 (7.2) 10.6 (7.9) .65
Medications
Number of medications, mean (s.d.) 10.1 (5.1) 9.8 (4.5) .71
≥ 80% adherent to oral hypoglycemic agent, n (%) 37 (42.0%) 33 (35.9%) .45
Functional status (SF-36)
Physical function score, mean (s.d.) 53.6 (31.7) 50.8 (32.6) .57
Social function score, mean (s.d.) 67.7 (39.9) 76.6 (36.9) .09
Role physical score, mean (s.d.) 49.4 (46.7) 59.5 (46.6) .15
Role emotional score, mean (s.d.) 65.9 (46.0) 67.8 (44.6) .82
Bodily pain score, mean (s.d.) 42.3 (31.4) 50.9 (31.7) .06
Cognitive status
MMSE, mean (s.d.) 28.2 (2.3) 28.2 (2.3) .80
Abbreviations: s.d., standard deviation; HS, high school; SF-36; Medical Outcomes Study Short Form; MMSE, Mini-Mental State Examination; 
PHQ-9, nine-item Patient Health Questionnaire; Hb, hemoglobin.
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